4Yukito Shinohara,Katsuya Nishimaru,Tohru Sawada,Akiro Terashi,Shunnosuke Handa,Shunsaku Hirai,Kunihiko Hayashi,Hideo Tohgi,Yasuo Fukuuchi,Shinichiro Uchiyama,Takenori Yamaguchi,Shotai Kobayashi,Kazuoki Kondo,Eiichi Otomo,Fumio Gotoh.Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial[J].Stroke.2008(6)
5Nancy K. Hills,S Claiborne Johnston.Trends in Usage of Alternative Antiplatelet Therapy After Stroke and Transient Ischemic Attack[J].Stroke.2008(4)
6Deepak L. Bhatt,Marcus D. Flather,Werner Hacke,Peter B. Berger,Henry R. Black,William E. Boden,Patrice Cacoub,Eric A. Cohen,Mark A. Creager,J. Donald Easton,Christian W. Hamm,Graeme J. Hankey,S. Claiborne Johnston,Koon-Hou Mak,Jean-Louis Mas,Gilles Montalescot,Thomas A. Pearson,P. Gabriel Steg,Steven R. Steinhubl,Michael A. Weber,Liz Fabry-Ribaudo,Tingfei Hu,Eric J. Topol,Keith A.A. Fox.Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial[J].Journal of the American College of Cardiology.2007(19)
7Graeme J Hankey,John W Eikelboom.Aspirin resistance[J].The Lancet.2006(9510)
8Sun U. Kwon,Yong-Jin Cho,Ja-Seong Koo,Hee-Joon Bae,Yong-Seok Lee,Keun-Sik Hong,Jun Hong Lee,Jong S. Kim.Cilostazol Prevents the Progression of the Symptomatic Intracranial Arterial Stenosis: The Multicenter Double-Blind Placebo-Controlled Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis[J].Stroke.2005(4)
9Hans-Christoph Diener,Julien Bogousslavsky,Lawrence M Brass,Claudio Cimminiello,Laszlo Csiba,Markku Kaste,Didier Leys,Jordi Matias-Guiu,Hans-Jürgen Rupprecht.Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial[J].The Lancet.2004(9431)
10Cary P. Gross,Eric W. Vogel,Abhay J. Dhond,Cheryl B. Marple,Roger A. Edwards,Ole Hauch,Elizabeth A. Demers,Michael Ezekowitz.Factors influencing physicians’ reported use of anticoagulation therapy in nonvalvular atrial fibrillation: A cross-sectional survey[J].Clinical Therapeutics.2003(6)
2Kaste M,Hacke W,Fieschi C,et al.Results of the European Cooperative Acute Stroke Study(ECASS)[].Cerebrovascular Diseases.1995
3Hsia AW,Sachdev HS,Tomlinson J,et al.Efficacy of IV tissue plasminogen activator in acute stroke:doesstroke subtype really matter-[].Neurology.2003
4Davis SM,Donnan GA,Parsons MW,et al.Effects of alteplase beyond3h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial(EPITHET):a placebo-controlled randomised trial[].The Lancet Neurology.2008
5Wahlgren N,Ahmed N,Dávalos A,et al.Thromboly-sis with alteplase3-4.5h after acute ischaemic stroke(SITS-ISTR):an observational study[].The Lancet.2008
6Hacke W,Kaste M,Bluhmki E,et al.for the ECASS investigators.Thrombolysis with Alteplase3to4.5hours after acute ischemic stroke[].The New England Journal of Medicine.2008
7Lyden P.Thrombolytic therapy for acute stroke--not a moment to lose[].The New England Journal of Medicine.2008
8Ergin A,Ergin N.Is thrombolytic therapy associated with increased mortality? Meta-analysis of random ized controlled trials[].Archives of Neurology.2005
9Hacke W,Kaste M,Fieschi C,et al.Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke(ECASS II)Second European-Australasian Acute Stroke Study In-vestigators[].The Lancet.1998
10Clark WM,Wissman S,Albers GW,et al.Recombinant tissue-type plasminogen activator(Alteplase)for ischemic stroke3to5hours after symptom onset.The ATLANTIS Study:a randomized con-trolled trial.Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke[].The Journal of The American Medical Association.1999
